162 related articles for article (PubMed ID: 15310550)
21. Insulin in the early management of diabetic complications.
Miles JM
J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
[TBL] [Abstract][Full Text] [Related]
22. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
Johnson JA; Majumdar SR
Am Heart J; 2004 Dec; 148(6):e27; author reply e28. PubMed ID: 15632864
[No Abstract] [Full Text] [Related]
23. Unsubstantiated concerns over the safety of use of sulphonylureas and insulin for increased risk of diabetes complications.
Weng J; Yang X
J Diabetes; 2014 Jan; 6(1):30-2. PubMed ID: 23944992
[No Abstract] [Full Text] [Related]
24. The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Rationale and guidelines.
Tiengo A; Del Prato S
Diabetes Res Clin Pract; 1988; 4 Suppl 1():75-81. PubMed ID: 3042339
[No Abstract] [Full Text] [Related]
25. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
[TBL] [Abstract][Full Text] [Related]
26. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
Molavi B; Rassouli N; Bagwe S; Rasouli N
Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
[TBL] [Abstract][Full Text] [Related]
27. Seeking sweet relief for diabetes.
Dove A
Nat Biotechnol; 2002 Oct; 20(10):977-81. PubMed ID: 12355109
[No Abstract] [Full Text] [Related]
28. [Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].
Störk S; Ertl G; Nitschmann S
Internist (Berl); 2010 May; 51(5):674-6. PubMed ID: 20352177
[No Abstract] [Full Text] [Related]
29. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
30. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidinediones and clinical outcomes in type 2 diabetes.
Retnakaran R; Zinman B
Lancet; 2009 Jun; 373(9681):2088-90. PubMed ID: 19501899
[No Abstract] [Full Text] [Related]
32. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Malesker MA
Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
[TBL] [Abstract][Full Text] [Related]
33. [Assessment of the management of type 2 diabetes].
Hanaire-Broutin H; Després JP; Dubois-Randé JL; Grimaldi A
Presse Med; 2004 Sep; 33(16):1121-3. PubMed ID: 15523273
[No Abstract] [Full Text] [Related]
34. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
[TBL] [Abstract][Full Text] [Related]
35. [Antidiabetic Drugs and the Kidney].
Candido R
G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
[No Abstract] [Full Text] [Related]
36. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes.
Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ
Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339
[TBL] [Abstract][Full Text] [Related]
37. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
38. Long-term comparative safety analysis of the risks associated with adding or switching to a sulfonylurea as second-line Type 2 diabetes mellitus treatment in a US veteran population.
Powell WR; Christiansen CL; Miller DR
Diabet Med; 2019 Nov; 36(11):1384-1390. PubMed ID: 30343492
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Bressler R; Johnson DG
Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
[TBL] [Abstract][Full Text] [Related]
40. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy.
Buse JB
Diabetes Care; 1999 Apr; 22 Suppl 3():C65-70. PubMed ID: 10189565
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
